Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma. Results of the ITCC-SIOPEN BEACON Immuno Phase II trial
Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma. Results of the ITCC-SIOPEN BEACON Immuno Phase II trial
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Weston, Rebekah
8f6d356c-3c02-46f0-830d-4017f56b9ffa
Owens, Cormac
93026ea7-0ee1-4c20-9023-0894567dfe57
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Weston, Rebekah
8f6d356c-3c02-46f0-830d-4017f56b9ffa
Owens, Cormac
93026ea7-0ee1-4c20-9023-0894567dfe57
Gray, Juliet C., Weston, Rebekah and Owens, Cormac
,
et al.
(2025)
Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma. Results of the ITCC-SIOPEN BEACON Immuno Phase II trial.
Journal of Clinical Oncology.
(In Press)
Text
BEACON Immuno paper 09-10-2025 accepted
- Accepted Manuscript
Restricted to Repository staff only until 6 October 2026.
Request a copy
More information
Accepted/In Press date: 6 October 2025
Identifiers
Local EPrints ID: 506786
URI: http://eprints.soton.ac.uk/id/eprint/506786
ISSN: 1527-7755
PURE UUID: a89a77ce-e858-4e01-af62-112e2a937ba9
Catalogue record
Date deposited: 18 Nov 2025 17:49
Last modified: 19 Nov 2025 02:39
Export record
Contributors
Author:
Rebekah Weston
Author:
Cormac Owens
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics